I hear you but assuming this company will grow revenue at a decent clip for the next several years, what valuation metric best captures its net present value per share??
Goldman, Citi, JPM, Jefferies, Bernstein, and many others on the street told you to sell MON. Now the ill-informed hedge funds with their 24 year old immigrant analysts are squealing.
And the stock closed at its highs for the day and up another couple after hours. Shorts are squealing...
The next step is a royalty agreement and an direct equity stake in SEED up to 49%
Even your basic street walker knows not to take the first offer, but that doesn't mean she doesn't want to dance. Stick around kid, and see how the real world operates...
You must have majored in poetry interpretation to be so skilled at reading between the lines. I for one don't put much currency in management press releases.
While the FDA isn’t mandated to abide by an SPA, it does give some assurance to FLML that the FDA at least agrees with FLML’s clinical trial plan. This is important because this will be FLML’s first “real” clinical trial. The Eclat approvals were “paper NDA’s” where the company didn’t have to generate any clinical data to file their NDA. Additionally FLML will be looking for approval for both cataplexy and excessive daytime sleepiness with one trial of ~250 people, where the original approval for Xyrem had an ~200 person trial for each indication.